Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Accured Expenses: 2013-2025

Historic Change in Accured Expenses for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $1.3 million.

  • Coherus Oncology's Change in Accured Expenses rose 125.33% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.6 million, marking a year-over-year increase of 37.11%. This contributed to the annual value of -$56.9 million for FY2024, which is 620.99% down from last year.
  • As of Q3 2025, Coherus Oncology's Change in Accured Expenses stood at $1.3 million, which was up 119.36% from -$6.6 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Change in Accured Expenses peaked at $40.9 million during Q3 2022, and registered a low of -$47.4 million during Q2 2024.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$5.0 million (2024), whereas its average is -$5.4 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 7,130.00% in 2021, then crashed by 2,313.51% in 2022.
  • Over the past 5 years, Coherus Oncology's Change in Accured Expenses (Quarterly) stood at $1.4 million in 2021, then slumped by 2,313.51% to -$31.1 million in 2022, then soared by 163.39% to $19.7 million in 2023, then tumbled by 130.27% to -$6.0 million in 2024, then surged by 125.33% to $1.3 million in 2025.
  • Its Change in Accured Expenses was $1.3 million in Q3 2025, compared to -$6.6 million in Q2 2025 and -$8.3 million in Q1 2025.